Genetic variation in antigen presentation and cancer immunotherapy

Lavanya Sivapalan, Valsamo Anagnostou

Research output: Contribution to journalComment/debatepeer-review


Human leukocyte antigen (HLA) molecules are critical mediators of anti-tumor immune responses. In this issue of Immunity,Chhibber et al. (2021) challenge previous associations between germline HLA zygosity and immunotherapy outcomes, demonstrating that germline HLA genotypes and diversity alone are not independent biomarkers of anti-PD1 clinical efficacy.

Original languageEnglish (US)
Pages (from-to)3-6
Number of pages4
Issue number1
StatePublished - Jan 11 2022

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Genetic variation in antigen presentation and cancer immunotherapy'. Together they form a unique fingerprint.

Cite this